Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OB756 Phase Ib/II study in myelofibrosis
ChiCTR2400090838Phase 2Completed
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bewintinib in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and myelofibrosis (MF) (8 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: p-STAT3 inhibition and Proportion of subjects with spleen volume reduction of at least 35% at 24 weeks. Started Oct 2024; status: completed.
02
Drugs
bewintinib
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)myelofibrosis (MF)
Beyond the preview
Go deeper on ChiCTR2400090838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090838.